NEW YORK (GenomeWeb) — Centogene said today that it has entered a 12-month strategic collaboration with Sarepta Therapeutics for the identification of patients with Duchenne muscular dystrophy in the Middle East and North Africa.
Under the terms of the agreement with Sarepta, Centogene will provide diagnostic services to physicians treating patients exhibiting symptoms related to DMD.
Financial and other terms of the agreement were not disclosed.
Rostock, Germany-based Centogene will conduct molecular diagnostic testing using deletion/duplication analysis and full-length sequencing of the DMD gene in patients testing negative by multiplex ligation-dependent probe amplification (MLPA).
The firm said that for testing, physicians can submit a patient sample using its CentoCard validated dried blood spot collection kit.